



---

# DEVONIAN

---

DEVONIAN HEALTH GROUP INC.

PRESS RELEASE

*For immediate release*

## **Devonian Health Group Announces presentation to the World Conference on Ageing and Gerontology and a correction on expiry date of warrants**

QUEBEC, January 23, 2020 – Devonian Health Group Inc. (“**Devonian**” or the “**Corporation**”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announced today that Dr. Andre P. Boulet, president and CEO and Dr. Nathalie Boucher, Director Research of the Corporation, will present at the World Conference on Ageing and Gerontology, which is being held in Lisbon, Portugal from August 10-11, 2020. The presentation will detail in vitro mechanisms of action of R-Spinasome® as well as outcomes of the clinical study comparing creams containing R-Spinasome® to two existing market-leading antioxidants.

“We are excited to present R-Spinasome® findings from *in vitro* and human studies at the World Conference on Ageing and Gerontology” stated Dr. André P. Boulet, Devonian’s President and Chief Executive Officer “We believe that science and skincare must intersect to deliver revolutionary advances in the exciting new world of botanical cosmeceuticals. R-Spinasome® forms a corner stone of our cosmeceutical program.” added Dr. Boulet.

The World Conference on Ageing and Gerontology event is expected to consist of Researchers and Academicians belonging to the realm of ageing and gerontology sharing their research at global platform.

### **Correction to October 17, 2019 Press release**

On October 17, 2019, Devonian issued a press release announcing the payment on the interest due on the debentures issued on July 19, 2019 and September 4, 2019, by the issuance of units. Each unit is comprised of one subordinate voting share and one warrant. It was mentioned that the expiry date of the warrants was 24 months, however it is 48 months.

### **About R-Spinasome®**

R-Spinasome® is a photosynthetic cell extract composed of pigments, proteins and lipids extracted from green leaves. The structure of this complex is critical to its function as an anti-oxidant, enabling it to capture and dissipate noxious energy generated by Reactive Oxygen Species (ROS), returning the complex to a state where it is ready to undergo new activation cycles. It is this dynamism and capacity to regenerate that provides R-Spinasome® complex with unprecedented, long lasting anti-oxidant activity. An independent study reported that the photosynthetic cell extract, in an in vitro model, protects against ultraviolet A (UVA) and ultraviolet B (UVB) damages<sup>1</sup>. In a clinical trial, creams composed of R-Spinasome®, outperformed two existing market-leading antioxidants<sup>2</sup>. The data from this clinical study highlights the efficacy and faster onset of action as seen by a statistical reduction of the total number of wrinkles after only one day of treatment, compared to PreVage® and LaMer®. R-Spinasome® is patent-protected in Japan, Canada, United States and Europe (#JP 5952261; #CDN 2,699,6765; #US 13/261,472, #EUR 11 768 299.7).



## About Devonian

Devonian Health Group Inc. is a late stage botanical pharmaceutical corporation with novel therapeutic approaches to targeting unmet medical needs. Devonian's core strategy is to develop prescription botanical drugs from plant materials and algae for the treatment of inflammatory-autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian's focus is further supported by a US-FDA set of regulatory guidelines favouring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines. Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Québec, Canada where it owns a state-of-the art extraction facility with full traceability 'from the seed to the pill'. Acquired in 2018, Altius Healthcare Inc., its commercialization partner, brings opportunities for further diversification and growth potential. Devonian is traded publicly on the TSXV Exchange (TSXv:GSD).

For more information, visit [www.groupedevonian.com](http://www.groupedevonian.com)

## References

1. St-Pierre A, et al. Study of antioxidant properties of thylakoids and application in UV protection and repair of UV-induced damage. *J Cosmet Dermatol.* 2019; 1-12.
2. Carroll, JM; Guenther, LC; Hanna, S and N Boucher, Comparison of topical antiaging creams in the management of lateral canthal lines. *J. Cosmet. Dermatol.* 2019; 00:1-11

## Forward Looking Statements

This press release contains forward-looking statements about Devonian's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, Devonian's ability to develop, manufacture, and successfully commercialize value-added pharmaceutical and dermo-cosmeceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Devonian to take advantage of business opportunities in the pharmaceutical and dermo-cosmeceutical industries, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations in Devonian's prospectus dated April 21<sup>st</sup>, 2017 under the heading "Risk Factors" related to Devonian's business. As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.

*Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.*



---

# DEVONIAN

---

**Contact:**

Dr André P. Boulet, PhD

President and Chief Executive Officer

Devonian Health Group inc.

Telephone: (514) 248-7509

Email: [apboulet@groupe-devonian.com](mailto:apboulet@groupe-devonian.com)